1. Inicio
  2. Publicaciones
  3. Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study

Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Sossa-Melo, C
  • Abello-Polo, V
  • Salazar, LA
  • Peña, AM
  • Luna-González, M
  • Cuervo-Lozada, D
  • Quintero-Vega, GE
  • Daza, J
  • Omaña-Orduz, OP
  • Mantilla, W
  • Perdomo, I
  • Galvez, K
  • Díaz-Correa, LM
  • Guerrero-Burbano, PA
  • Herrera, JM
  • Idrobo, H
  • Gaviria, LM
  • Correa-Correa, ME
  • Lobaton, J
  • Bermúdez, CD
  • Pedraza-Morales, JE
  • Serrano-Casas, JC
  • Jaramillo, F
  • Gómez, R
  • Rosales, C
  • Solano, MH
  • Varón, C

Grupos

Abstract

There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range:60-98), 55% were men, 61% had an ECOG < 2, and 75.5% had de novo AML. FLT3-ITD or NPM1 mutations were performed in 23.4% and 15.6% patients, and detected in 14.3% and 16.7% of cases, respectively. Treatment included intensive chemotherapy (IC) (36.8%), Low-Intensity Regimen Based on Low-Dose Cytarabine (LDAC-based) (12.6%), hypomethylating agents (HMAs, with/without venetoclax) (35.3%), and supportive care (15.2%). The overall survival (OS) rate was 35.2% at 1 year and 5.6% at 5 years (13.7% for IC, 9.4% for LDAC-based, and 0% for other treatments); with median OS of 8.2 months (10.6 months after IC, 8.8 months after non-IC, 8.9 months after azacitidine/decitabine, 8.2 months after azacitidine-venetoclax, and 1.9 months with supportive care). Only 1.5% of patients underwent a transplant in the first line. The Leukemia-free survival (LFS) rate was 45.8% at 1-year and 13.7% at 5-years (22.4% for IC, 9.4% and 0% for other treatments); with median LFS of 9.5 months (17.3 months after IC, 7.4 months after LDAC-based, and 10.8 months after HMA). This study provides new insights into the management of patients in Colombia, highlighting the need for a highly individualized approach in treating AML in elderly patients.

© 2025. The Author(s).

Datos de la publicación

ISSN/ISSNe:
0939-5555, 1432-0584

ANNALS OF HEMATOLOGY  SPRINGER

Tipo:
Article
Páginas:
369-381
PubMed:
39815122
Factor de Impacto:
0,994 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 1

Documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Acute myeloid leukemia; Treatment outcomes; Elderly patients; Overall survival

Campos de Estudio

Cita

Compartir